Quoin Pharmaceuticals Ltd.: EMA grants orphan drug designation to QRX003

What happened

• On Oct 14, 2026, Quoin Pharmaceuticals Ltd announced that its lead product candidate QRX003 has been granted Orphan Drug Designation in Europe by the European Medicines Agency (the EMA) for the treatment of Peeling Skin Syndrome. The filing states a press release announcing the designation is attached as Exhibit 99.1 to the Form 8-K and is incorporated by reference.

Key details

• Orphan Drug Designation in Europe provides incentives including scientific advice on study protocols, various fee reductions and access to EU grants, according to the filing.
• If approved for marketing by the EMA, QRX003 would receive 10 years of market exclusivity in Europe for similar medicines treating Peeling Skin Syndrome.
• The company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end.

Why it may matter

• The Form 8-K reports Item 7.01 (Regulation FD disclosure) and Item 8.01 (other events); Item 7.01 covers the press release disclosure and Item 8.01 describes the EMA designation and related regulatory incentives and plans for a clinical study.
• A filing does not show why the insider traded or why the company acted.